Revenue segments as reported by the company.

MedSurg and Neurotechnology

Orthopaedics and Spine

Orthopaedics

MedSurg

Neurotechnology and Spine

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research, development and engineering

Selling, general and administrative

Recall charges

Amortization of intangible assets

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Stryker

MAKO was a publicly traded medical device company based in Florida. On September 25, 2013, the Board of Directors of Mako Surgical accepted a deal to be acquired by Stryker for $1.65B. The deal closed in December 2013. The company manufactures and markets surgical robotic arm assistance platforms, most notably the RIO as well as orthopedic implants used by orthopedic surgeons for use in partial knee and total hip arthroplasty. They are known for their intellectual property of devices and have over 300 U.S. and foreign patents and patent applications.

MAKO Surgical Corp

Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The Orthopaedics and Spine segment focuses on implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems used in spinal injury, deformity, and degenerative therapies. The company was founded by Homer H. Stryker in 1941 and is headquartered in Portage, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Stryker (SYK) exceeds Q4 expectations, poised for growth in 2023

Stryker (SYK) delivered exceptional financial results in Q4 2022, surpassing expectations and demonstrating resilience amid challenges. The company is well-positioned for growth with a strong pipeline of products and a focus on margin expansion. Despite ongoing market complexities, Stryker remains optimistic about its future performance.

Stryker reports robust Q1 results and optimistic outlook for 2023

Stryker's strong Q1 performance driven by organic sales growth and increased EPS, with positive outlook for the full year.
Company recognized for workplace excellence, leading in robotics, and expecting growth in medical division.
Challenges include supply chain uncertainties, margin impacts, and market disruptions, but opportunities lie in stakeholder engagement and business expansion.
Overall, Stryker remains focused on innovation, debt reduction, and strategic acquisitions for future growth.

Stryker reports stellar Q2 results, eyes international growth opportunities

Stryker's Q2 performance reflects robust sales growth, margin improvement, and strategic acquisitions driving financial strength.
While facing challenges in the U.S. market and competitive landscapes, Stryker's focus on innovation and international growth presents promising opportunities.
The company's financial resilience, debt reduction strategy, and upcoming product launches position Stryker for sustained success and market expansion.
Overall, Stryker's strong performance, coupled with a focus on innovation and strategic growth initiatives, sets a positive trajectory for future success.

Stryker reports robust Q3 earnings, eyes international growth and M&A

Stryker's Q3 performance reflects strong sales growth and earnings increase, driven by key segments and product lines. Challenges include market competition and potential shifts in procedure trends, while opportunities exist in international expansion and strategic acquisitions.

Stryker exceeds $20B in sales, eyes continued growth and innovation

Stryker's Q4 performance showcased strong sales growth, margin expansion, and successful acquisitions, positioning the company for continued success.
While facing challenges in pricing and potential regulatory impacts, Stryker's focus on innovation and strategic growth initiatives presents promising opportunities.
The company's robust pipeline of innovative products and successful integration efforts highlight its resilience and potential for sustained growth.
With a solid financial foundation and strategic vision, Stryker is well-positioned to capitalize on market opportunities and drive future profitability.

Stryker reports strong Q1 growth, eyes international expansion opportunities

Stryker's Q1 2024 earnings call reflects strong performance, with double-digit organic sales growth and increased guidance for the full year.
The company's focus on innovation, successful acquisitions, and market recognition position it well for future growth and leadership in key segments.
While facing challenges like regulatory delays and market dependencies, Stryker remains optimistic about meeting targets and driving growth through new products and acquisitions.
Opportunities in international expansion, AI solutions, and continued market growth present avenues for sustained success and market leadership for Stryker.

Stryker reports robust Q2 earnings, raises 2024 outlook on acquisitions and margin expansion

Stryker's strong Q2 performance, strategic acquisitions, and focus on margin expansion position the company for continued growth. Despite challenges like foreign exchange rates and market softness in certain segments, Stryker's product strength, innovation pipeline, and international growth opportunities offer a positive outlook. With a commitment to driving margins and expanding its product portfolio, Stryker remains poised for sustained success in the medical technology industry.

Stryker reports robust Q3 performance with strong growth and strategic acquisitions

Stryker's Q3 showcased strong organic sales and EPS growth, driven by MedSurg and Neurotechnology segments.
Strategic acquisitions, record Mako installations, and operational efficiency improvements underpin performance.
Challenges in the ischemic stroke segment and competitor actions pose risks, while pricing trends and margin efficiencies are under scrutiny.
Opportunities lie in M&A expansion, growth in high-demand areas, and sustained market momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Stryker (NYSE:SYK) reported its Q3 earnings results on Thursday, October 28, 2021 at 04:05 PM. Here's what investors need to know about the announcement.

Recap: Stryker Q3 Earnings

Kalamazoo, MI, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the third quarter of 2021:

Stryker reports third quarter 2021 operating results

Stryker's (SYK) third-quarter results are likely to reflect strong segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.

Stryker (SYK) to Report Q3 Earnings: What's in the Cards?

Stryker is a leading medical device company with over 4,000 patents in the U.S. It's also a dividend aristocrat, and it has a resilient business that continues to demonstrate impressive growth.

Why Stryker Is A Gift For Growth Investors

Kalamazoo, Michigan, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will host an Analyst Meeting on Thursday, November 18, 2021, at 2:30 p.m. Eastern Time, in Mahwah, New Jersey.

Stryker to host analyst meeting

We think that Stryker stock (NYSE: SYK) currently is a better pick compared to Boston Scientific stock, despite Stryker being slightly more expensive of the two. Stryker trades at about 6.4x trailing revenues, compared to 5.7x for Boston Scientific.

This Stock Is Likely To Outperform Boston Scientific

Air Products and Chemicals

Bristol-Myers

Comcast

Cisco Systems

General Dynamics

Illinois Tool Works

JPMorgan Chase & Co

Mastercard

Main Street Capital

Nucor

Realty Income Corp

Toronto-Dominion Bank

Verizon

W. P. Carey

We provide a summary of upcoming ex-dividend dates in a quick reference table. The table includes relevant data and key statistics as well as the next payout and pay date.

Upcoming Ex-Dividend Dates: September 28-October 11, 2021

Asensus Surgical

Intuitive Surgical

Medtronic

Watch out for the likes of Asensus Surgical (ASXC), Stryker (SYK), Medtronic (MDT) and Intuitive Surgical (ISRG) as demand for surgical robots is set to rise, owing to the conveniences they offer.

4 Stocks to Watch as Demand for Surgical Robots Ready to Rise

Kalamazoo, Michigan, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will host a conference call on Thursday, October 28, 2021 at 4:30 p.m., Eastern Time, to discuss the Company's operating results for the quarter ended September 30, 2021 and provide an operational update. Final operating results for the quarter ended September 30, 2021 will be released at 4:05 p.m. that day.

Stryker to host conference call on October 28, 2021

OrthoPediatrics

Orthofix International

SeaSpine Holdings

Zimmer Biomet Hlds

OrthoPediatrics (KIDS), Orthofix (OFIX), Zimmer Biomet (ZBH), Stryker (SYK) and SeaSpine (SPNE) are expected to hold ground despite a challenging business climate.

5 Stocks to Deflect Delta Variant Curveball From Orthopedic Space

Broadcom

Philip Morris

STAG Industrial

STORE Capital

Upcoming Ex-Dividend Dates: September 21-October 4, 2021

The newly launched Citrelock Tendon Fixation Device System expands Stryker's (SYK) Foot & Ankle offerings.

Stryker's (SYK) Trauma & Extremities Arm Unveils New Product

MAHWAH, N.J.--(BUSINESS WIRE)--Stryker's Trauma & Extremities division has launched its Citrelock™ Tendon Fixation Device System. The new system provides surgeons a differentiated design via a tendon thread featuring a resorbable technology, known as Citregen™, that has unique chemical and mechanical properties for orthopaedic surgical applications. Stryker will debut Citrelock at the American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting, Sept. 22-25, 2021, in Charlotte, N.C.

Stryker Launches New Tendon Fixation Device System

Medical device companies are gradually seeing a rebound in their business as fewer elective medical visits, procedures and surgeries are being delayed due to Covid-19.

Stryker Corp: A Health Care Company You Shouldn't Ignore

Investors are optimistic about Stryker's (SYK) strength in robotics and its diversified product portfolio.

Stryker (SYK) Hits New 52-Week High: What's Driving It?

Stryker Corporation (NYSE: SYK) has acquired Gauss Surgical for an undisclosed consideration. Gauss Surgical is a medical device company that has developed Triton, an artificial intelligence-enabled platform for real-time monitoring of blood loss during surgery.

Stryker Acquires Provider Of Blood Loss Monitoring Platform

FREMONT, Calif., Sept. 1, 2021 /PRNewswire/ -- THINK Surgical, Inc., an innovator in the field of orthopedic surgical robots, today announced the appointment of Stuart F.

Stuart F. Simpson is THINK Surgical's New President and Chief Executive Officer

Kalamazoo, Michigan, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in Morgan Stanley's 19th Annual Global Healthcare Conference on Monday, September 13, 2021.

Stryker to participate in Morgan Stanley's 19th Annual Global Healthcare Conference

MAHWAH, N.J.--(BUSINESS WIRE)--Stryker's T2 Alpha Femur Retrograde Nailing System features a redefined data-driven nail design, a dedicated proximal targeting system, and more.

Stryker Launches T2 Alpha Femur Retrograde Nailing System

UnitedHealth Group

Zai Lab Ltd.

The Vanguard Health Care Fund (Trades, Portfolio) has revealed its portfolio for the second quarter of this year. Major trades for the fund include a reduction in its portfolio-leading UnitedHealth Group Inc. ( UNH , Financial) position, selling out of its PPD Inc. ( PPD , Financial) and Smith & Nephew PLC ( LSE:SN.

The Vanguard Health Care Fund's Top 5 Trades of the 2nd Quarter

The company's second-quarter results suggest it boasts positive operating fundamentals and a decent balance sheet.

Is This Medical-Device Company a Buy After Solid Earnings?

Kalamazoo, Michigan, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.63 per share payable October 29, 2021 to shareholders of record at the close of business on September 30, 2021, representing an increase of 9.6% versus the prior year and unchanged from the previous quarter.

Stryker declares a $0.63 per share quarterly dividend

Apple

Accenture Plc

Automatic Data Processing

CME Group

Costco

Home Depot

Honeywell

Intel

Johnson & Johnson

Eli Lilly

Lockheed Martin

Merck

Microsoft

NIKE

PepsiCo

Procter & Gamble

Texas Instruments

Union Pacific

Visa

Walmart

This article updates one published by David Van Knapp in June 2020.

The Highest Quality Dividend Growth Stocks

News for Stryker Stock (SYK)